OraSure Technologies (NASDAQ:OSUR) Announces Quarterly Earnings Results, Misses Estimates By $0.08 EPS

OraSure Technologies (NASDAQ:OSUR) issued its quarterly earnings results on Wednesday. The medical instruments supplier reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08), FiscalAI reports. OraSure Technologies had a negative return on equity of 16.45% and a negative net margin of 59.76%.

Here are the key takeaways from OraSure Technologies’ conference call:

• Management expects mid-year FDA clearances and commercial launches for its CT/NG rapid molecular OTC self-test and the Colli‑Pee at‑home urine collection device, with revenue ramps anticipated in the second half of 2026.
• Q1 revenue was $27.9 million (above guidance midpoint) and non‑GAAP gross margin expanded to 43.4%, driven by insourcing production into its Pennsylvania facilities and improved operating efficiencies.
• OraSure finished Q1 with $177 million cash and zero debt while returning $20 million to shareholders via buybacks over the last four quarters, but operating cash flow was negative $14 million with management targeting break‑even cash flow in 2027.
• International progress includes initial orders to a nearshoring partner, planned follow‑on orders in H2, and expanded reach for Sickle SCAN via BioMedomics integration and national health program relationships.
• Operating expenses remain elevated—Q1 R&D was $13.7 million (launch preparation) and G&A rose due to severance and one‑time items—contributing to a GAAP operating loss of $23.3 million, though management expects R&D and G&A to normalize later in 2026.

OraSure Technologies Stock Performance

OSUR remained flat at $3.00 during trading on Wednesday. 583,251 shares of the company’s stock traded hands, compared to its average volume of 324,072. OraSure Technologies has a 12 month low of $2.08 and a 12 month high of $3.82. The stock’s 50-day moving average is $3.05 and its 200 day moving average is $2.76. The stock has a market capitalization of $215.91 million, a price-to-earnings ratio of -3.23 and a beta of 0.89.

Insider Activity at OraSure Technologies

In other OraSure Technologies news, CEO Manner Carrie Eglinton acquired 32,300 shares of the firm’s stock in a transaction on Friday, March 20th. The stock was bought at an average cost of $2.93 per share, for a total transaction of $94,639.00. Following the completion of the purchase, the chief executive officer directly owned 2,190,874 shares in the company, valued at $6,419,260.82. This represents a 1.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kenneth J. Mcgrath bought 32,300 shares of the firm’s stock in a transaction dated Friday, March 20th. The stock was purchased at an average price of $2.93 per share, with a total value of $94,639.00. Following the completion of the purchase, the chief financial officer directly owned 589,562 shares of the company’s stock, valued at approximately $1,727,416.66. This trade represents a 5.80% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have acquired 108,643 shares of company stock valued at $321,407. 3.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OSUR. Amundi purchased a new position in shares of OraSure Technologies in the first quarter valued at $47,000. AQR Capital Management LLC boosted its stake in shares of OraSure Technologies by 48.3% in the first quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier’s stock valued at $3,511,000 after purchasing an additional 339,493 shares during the period. NewEdge Advisors LLC boosted its stake in shares of OraSure Technologies by 32,595.9% in the first quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier’s stock valued at $161,000 after purchasing an additional 47,590 shares during the period. Empowered Funds LLC boosted its stake in shares of OraSure Technologies by 7.2% in the first quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier’s stock valued at $1,366,000 after purchasing an additional 27,310 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in shares of OraSure Technologies by 32.7% in the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 8,133 shares during the period. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of OraSure Technologies in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.